The Effects of Cannabidiol on Canine Epilepsy and Arthritis – a Case Study

Abstract

Cannabidiol oil (CBD) has gained notoriety in recent years due to its effectiveness as an adjuvant therapy in many pathologies.The purpose of this study is to evaluate the effects of CBD in the management of pain and the associated pathologies of epilepsy and arthritis, on a single subject, a female Labrador, 12.5 years old at the beginning of the study. The therapeutic protocol used was the administration of CBD oil, sublingually, in doses of 2.25 mg/kg/day. Hematology and biochemistry were performed at 3, 6 and 12 months. Radiology was performed before the study began and after 6 months.After the first month, a decrease in the number and severity of epilepsy crises was observed. Beginning with the first 2 weeks of CBD oil administration, the patient was already experiencing an improvement in her mobility along with general pain remittance and the amelioration of her 3rd degree lameness, quantified by the Colorado Pain Scale. After 5 months of CBD administration, with no seizures recorded, phenytoin therapy was ceased. After 8 months, phenobarbital was also excluded from the therapeutic protocol, thus making CBD an independent the rapeutic molecule. CBD appears to be a useful molecule in managing both pain and epilepsy.